Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEONEL REYES JR.

Allopathic & Osteopathic Physicians Family Medicine

NPI
1841302049
CMS profile
220107
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,847.77

31 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $998.83 28
Travel and Lodging $848.94 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Research & Development, LLC $1,138.94 9
ITI, Inc. $308.41 13
Teva Pharmaceuticals USA, Inc. $145.59 2
Intuity Medical Inc $115.28 1
Alkermes, Inc. $85.93 1
ABBVIE INC. $53.62 5

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEONEL REYES JR.

NPI 1841302049 · CMS profile ID 220107

Allopathic & Osteopathic Physicians / Family Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841302049?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841302049?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841302049?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1841302049?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

31 matching records · $1,847.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 31 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–31 of 31.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ITI, Inc. $18.4111/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673233 CMS
ABBVIE INC. $9.0011/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998222571 CMS
ITI, Inc. $123.5311/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673225 CMS
ITI, Inc. $16.9510/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673219 CMS
Intuity Medical Inc $115.2809/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997155523 CMS
Teva Pharmaceuticals USA, Inc. $17.3409/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056989907 CMS
Alkermes, Inc. $85.9309/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022902487 CMS
Teva Pharmaceuticals USA, Inc. $128.2509/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056989965 CMS
ITI, Inc. $15.6608/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673211 CMS
ITI, Inc. $17.6608/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673203 CMS
ITI, Inc. $21.0706/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673193 CMS
ITI, Inc. $10.6006/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673187 CMS
ITI, Inc. $21.8805/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673179 CMS
Janssen Research & Development, LLC $165.0005/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061054825 CMS
Janssen Research & Development, LLC $25.0005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061054831 CMS
Janssen Research & Development, LLC $125.0005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061054837 CMS
Janssen Research & Development, LLC $292.0805/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061054843 CMS
Janssen Research & Development, LLC $40.0005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061054849 CMS
Janssen Research & Development, LLC $20.0005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061054853 CMS
Janssen Research & Development, LLC $60.0005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061054857 CMS
Janssen Research & Development, LLC $20.0005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061054863 CMS
Janssen Research & Development, LLC $391.8604/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061054819 CMS
ABBVIE INC. $24.5204/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998222569 CMS
ABBVIE INC. $6.1204/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998222567 CMS
ITI, Inc. $13.1902/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673171 CMS
ITI, Inc. $21.9802/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673163 CMS
ABBVIE INC. $5.5002/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998222565 CMS
ITI, Inc. $16.2202/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673147 CMS
ITI, Inc. $3.0002/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673157 CMS
ABBVIE INC. $8.4801/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998222563 CMS
ITI, Inc. $8.2601/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040673139 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $382.31 5
PY2020 $516.96 25
PY2021 $254.93 16
PY2022 $565.96 18
PY2023 $1,847.77 31
PY2024 $2,875.29 31
PY2025 $3,306.12 27

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $755,211.02 111
PY2024 Recipient $1,229.18 7
PY2024 Principal investigator $859,657.92 144
PY2023 Recipient $884.12 7
PY2023 Principal investigator $2,118,069.52 144
PY2022 Recipient $3,289.97 13
PY2022 Principal investigator $555,785.63 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

151 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $63.00 12/31/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
M24-885 ABBV-766 Ph 2 PoC Combo study (066 + 981;323; 382) No dispute reported 06/30/2026 1100765057
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,799.59 12/31/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1155804926
Principal investigator 1 PFIZER INC. $11,982.00 12/31/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130968861
Principal investigator 1 PFIZER INC. $34,614.06 12/19/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130968679
Principal investigator 1 Chiesi USA, Inc. $610.00 12/18/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148225950
Principal investigator 1 Janssen Research & Development, LLC $4,007.00 12/18/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983577
Principal investigator 1 Janssen Research & Development, LLC $4,950.00 12/16/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983571
Principal investigator 1 ABBVIE INC. $12,758.88 12/05/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100759365
Principal investigator 1 ABBVIE INC. $2,044.80 12/05/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1100760045
Principal investigator 1 Kiniksa Pharmaceuticals International, plc $2,200.00 12/05/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjgren's Disease No dispute reported 06/30/2026 1154867598
Principal investigator 1 PFIZER INC. $20,028.52 12/05/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130968855
Principal investigator 1 PFIZER INC. $4,117.36 11/27/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130983560
Principal investigator 1 ABBVIE INC. $550.00 11/26/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1100756565
Principal investigator 1 Janssen Research & Development, LLC $8,282.00 11/20/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983451
Principal investigator 1 SANOFI US SERVICES INC. $3,160.08 11/20/2024 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1128720697
Recipient ABBVIE INC. $717.95 11/15/2024 Covered Recipient Physician A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1100681279
Recipient ABBVIE INC. $24.99 11/15/2024 Covered Recipient Physician A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1100681281
Recipient ABBVIE INC. $50.00 11/15/2024 Covered Recipient Physician A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1100681283
Recipient ABBVIE INC. $22.63 11/15/2024 Covered Recipient Physician A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1100681285
Recipient ABBVIE INC. $50.00 11/15/2024 Covered Recipient Physician A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1100681287
Principal investigator 1 Chiesi USA, Inc. $2,361.00 11/15/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148225106
Recipient ABBVIE INC. $220.71 11/14/2024 Covered Recipient Physician A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1100681275
Recipient ABBVIE INC. $142.90 11/14/2024 Covered Recipient Physician A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1100681277
Principal investigator 1 Janssen Research & Development, LLC $362.00 11/14/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1079012608
Principal investigator 1 ABBVIE INC. $11,500.00 11/07/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 1100753591
Principal investigator 1 ABBVIE INC. $3,692.00 11/07/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100753593
Principal investigator 1 PFIZER INC. $26,064.36 11/05/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130983566
Principal investigator 1 Chiesi USA, Inc. $2,000.00 11/01/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148224508
Principal investigator 1 Janssen Research & Development, LLC $724.00 10/28/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1079012604
Principal investigator 1 PFIZER INC. $29,955.00 10/24/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1130996920
Principal investigator 1 Chiesi USA, Inc. $2,361.00 10/23/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148224278
Principal investigator 1 Janssen Research & Development, LLC $5,257.00 10/23/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983611
Principal investigator 1 Ardelyx, Inc. $1,600.00 10/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1146668070
Principal investigator 1 Kiniksa Pharmaceuticals International, plc $7,000.00 10/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjgren's Disease No dispute reported 06/30/2026 1154867600
Principal investigator 1 Kiniksa Pharmaceuticals International, plc $2,162.00 10/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjgren's Disease No dispute reported 06/30/2026 1154867602
Principal investigator 1 Kiniksa Pharmaceuticals International, plc $550.00 10/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjgren's Disease No dispute reported 06/30/2026 1154867604
Principal investigator 1 Kiniksa Pharmaceuticals International, plc $2,000.00 10/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjgren's Disease No dispute reported 06/30/2026 1154867608
Principal investigator 1 Janssen Research & Development, LLC $320.00 10/14/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1079012602
Principal investigator 1 Chiesi USA, Inc. $550.00 10/11/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148224124
Principal investigator 1 Chiesi USA, Inc. $425.00 10/09/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148223866
Principal investigator 1 Chiesi USA, Inc. $2,361.00 10/09/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148223868
Principal investigator 1 Chiesi USA, Inc. $576.00 10/09/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148223870
Principal investigator 1 Chiesi USA, Inc. $2,200.00 10/09/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148224006
Principal investigator 1 ABBVIE INC. $5,078.40 10/03/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100746080
Principal investigator 1 ModernaTX, Inc. $15,697.94 10/01/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189903
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 09/25/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983965
Principal investigator 1 Janssen Research & Development, LLC $4,206.00 09/18/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983797
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/18/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189885
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/18/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189887
Principal investigator 1 ModernaTX, Inc. $1,552.00 09/18/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189889
Principal investigator 1 ModernaTX, Inc. $1,552.00 09/18/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189891
Principal investigator 1 ModernaTX, Inc. $1,552.00 09/18/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189893
Principal investigator 1 ModernaTX, Inc. $1,344.00 09/18/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189895
Principal investigator 1 ModernaTX, Inc. $340.00 09/18/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189897
Principal investigator 1 Bausch Health US, LLC $8,536.25 09/16/2024 Non-covered Recipient Entity
Sun Research Institute, LLC
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 1151684954
Principal investigator 1 PFIZER INC. $13,284.00 09/10/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131025680
Principal investigator 1 Ardelyx, Inc. $1,600.00 09/09/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1146667936
Principal investigator 1 ABBVIE INC. $2,212.48 09/04/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1100739850
Principal investigator 1 ABBVIE INC. $3,692.00 09/04/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100740326
Principal investigator 1 Janssen Research & Development, LLC $2,200.00 09/04/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983565
Principal investigator 1 PFIZER INC. $3,178.00 08/27/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131028985
Principal investigator 1 ModernaTX, Inc. $500.00 08/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189879
Principal investigator 1 Janssen Research & Development, LLC $7,179.00 08/19/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983717
Principal investigator 1 SANOFI US SERVICES INC. $1,350.00 08/16/2024 Non-covered Recipient Entity
Sun Research Institute
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1128703787
Principal investigator 1 ModernaTX, Inc. $4,287.96 08/14/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147190113
Principal investigator 1 PFIZER INC. $17,580.00 08/06/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131028420
Principal investigator 1 ABBVIE INC. $2,776.80 08/02/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100734680
Principal investigator 1 ModernaTX, Inc. $850.00 07/31/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147190105
Principal investigator 1 Janssen Research & Development, LLC $1.00 07/26/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983609
Principal investigator 1 ABBVIE INC. $710.40 07/16/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1100729984
Principal investigator 1 Chiesi USA, Inc. $1,075.00 07/12/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148221318
Principal investigator 1 Chiesi USA, Inc. $800.00 07/12/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148221320
Principal investigator 1 PFIZER INC. $2,371.12 07/11/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131044584
Principal investigator 1 ABBVIE INC. $2,212.48 07/05/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1100727362
Principal investigator 1 ABBVIE INC. $11,195.04 07/05/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100728142
Principal investigator 1 Chiesi USA, Inc. $100.00 07/03/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148221150
Principal investigator 1 Chiesi USA, Inc. $200.00 07/03/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148221152
Principal investigator 1 Chiesi USA, Inc. $1,700.00 07/03/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148221154
Principal investigator 1 ModernaTX, Inc. $18,163.16 07/03/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189865
Principal investigator 1 ModernaTX, Inc. $343.78 07/03/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147190103
Principal investigator 1 Ardelyx, Inc. $1,600.00 07/01/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1146667809
Principal investigator 1 ModernaTX, Inc. $414.22 06/27/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147190111
Principal investigator 1 ModernaTX, Inc. $4,656.00 06/26/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147190109
Principal investigator 1 PFIZER INC. $10,077.26 06/26/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131069072
Principal investigator 1 GlaxoSmithKline, LLC. $6,975.00 06/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1127535302
Principal investigator 1 ModernaTX, Inc. $8,950.00 06/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189859
Principal investigator 1 ModernaTX, Inc. $1,800.00 06/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189861
Principal investigator 1 ModernaTX, Inc. $2,000.00 06/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189863
Principal investigator 1 Janssen Research & Development, LLC $2,295.00 06/14/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983545
Principal investigator 1 Chiesi USA, Inc. $4,584.00 06/07/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148220472
Principal investigator 1 Chiesi USA, Inc. $247.44 05/29/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148220104
Principal investigator 1 Chiesi USA, Inc. $1,552.00 05/29/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148220106
Principal investigator 1 Bausch Health US, LLC $9,786.25 05/24/2024 Non-covered Recipient Entity
Sun Research Institute, LLC
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 1151684936
Principal investigator 1 Chiesi USA, Inc. $4,584.00 05/24/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148220070
Principal investigator 1 Chiesi USA, Inc. $2,292.00 05/24/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1148220072
Principal investigator 1 PFIZER INC. $4,097.02 05/24/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131079821
Principal investigator 1 Janssen Research & Development, LLC $4,607.00 05/22/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983771
Principal investigator 1 Chiesi USA, Inc. $1,125.00 05/16/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219918
Principal investigator 1 ABBVIE INC. $4,610.40 05/09/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100717920
Principal investigator 1 SANOFI PASTEUR INC. $6,000.00 05/02/2024 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128701290
Principal investigator 1 PFIZER INC. $9,135.65 04/26/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131087837
Principal investigator 1 PFIZER INC. $460.80 04/25/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131087993
Principal investigator 1 ABBVIE INC. $1,700.00 04/22/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1100714670
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 04/22/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1079012606
Principal investigator 1 Chiesi USA, Inc. $1,000.00 04/15/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218763
Principal investigator 1 Chiesi USA, Inc. $1,800.00 04/15/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218765
Principal investigator 1 Chiesi USA, Inc. $4,722.00 04/12/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148218719
Principal investigator 1 SANOFI US SERVICES INC. $2,167.90 04/10/2024 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1128720657
Principal investigator 1 Ardelyx, Inc. $1,728.00 04/09/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1146667655
Principal investigator 1 PFIZER INC. $6,113.90 04/05/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131087843
Principal investigator 1 ABBVIE INC. $10,776.00 04/04/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100712642
Principal investigator 1 ABBVIE INC. $2,044.80 04/04/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1100712826
Principal investigator 1 ABBVIE INC. $1,700.00 04/03/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1100710710
Principal investigator 1 PFIZER INC. $7,384.75 04/02/2024 Non-covered Recipient Entity
Sun Research Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1131087849
Principal investigator 1 ModernaTX, Inc. $12,850.00 03/28/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147190107
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,025.54 03/27/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1110835783
Principal investigator 1 ModernaTX, Inc. $18,163.16 03/27/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189833
Principal investigator 1 PFIZER INC. $4,986.19 03/26/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131103137
Principal investigator 1 Janssen Research & Development, LLC $3,028.00 03/25/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983689
Principal investigator 1 Ardelyx, Inc. $4,161.00 03/22/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
TEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS No dispute reported 06/30/2026 1146667623
Principal investigator 1 ABBVIE INC. $1,433.60 03/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100709057
Principal investigator 1 ABBVIE INC. $6,375.00 03/21/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100709107
Principal investigator 1 ABBVIE INC. $537.60 03/20/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100708799
Principal investigator 1 SANOFI US SERVICES INC. $932.00 03/15/2024 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1128720639
Principal investigator 1 Bausch Health US, LLC $450.00 03/14/2024 Non-covered Recipient Entity
Sun Research Institute, LLC
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 1151684950
Principal investigator 1 ModernaTX, Inc. $946.04 03/13/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147189835
Principal investigator 1 ABBVIE INC. $2,096.00 03/07/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100707086
Principal investigator 1 ABBVIE INC. $9,175.92 03/07/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1100707450
Principal investigator 1 Janssen Research & Development, LLC $5,054.00 03/04/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983933
Principal investigator 1 SANOFI US SERVICES INC. $11,454.04 03/01/2024 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1128720649
Principal investigator 1 SANOFI US SERVICES INC. $75.00 02/28/2024 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1128720641
Principal investigator 1 ABBVIE INC. $80.00 02/27/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1100705036
Principal investigator 1 PFIZER INC. $5,135.01 02/24/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131103143
Principal investigator 1 ModernaTX, Inc. $117,950.45 02/23/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147189827
Principal investigator 1 PFIZER INC. $10,137.60 02/21/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131103132
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,314.49 02/20/2024 Non-covered Recipient Entity
Sun Research Institute
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) No dispute reported 06/30/2026 1123480008
Principal investigator 1 Bausch Health US, LLC $19,144.40 02/19/2024 Non-covered Recipient Entity
Sun Research Institute, LLC
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 1151684941
Principal investigator 1 Chiesi USA, Inc. $195.95 02/15/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148216092
Principal investigator 1 Chiesi USA, Inc. $183.70 02/15/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148216094
Principal investigator 1 ModernaTX, Inc. $10,534.41 02/09/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147189825
Principal investigator 1 PFIZER INC. $7,247.32 02/06/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131103172
Principal investigator 1 Janssen Research & Development, LLC $1,666.00 01/26/2024 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 1078983633
Principal investigator 1 PFIZER INC. $12,968.16 01/26/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131107161
Principal investigator 1 PFIZER INC. $385.43 01/17/2024 Non-covered Recipient Entity
Sun Research Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1131109309
Principal investigator 1 ABBVIE INC. $2,500.00 01/11/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100699895
Principal investigator 1 ABBVIE INC. $1,500.00 01/11/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 1100699897
Principal investigator 1 ABBVIE INC. $2,500.00 01/10/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1100699203
Principal investigator 1 Chiesi USA, Inc. $8,910.00 01/10/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148214273
Principal investigator 1 PFIZER INC. $54,938.06 01/09/2024 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1131108050
Principal investigator 1 Bausch Health US, LLC $3,750.00 01/08/2024 Non-covered Recipient Entity
Sun Research Institute, LLC
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 1151684945
Principal investigator 1 ABBVIE INC. $550.00 01/04/2024 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1100698111